337 related articles for article (PubMed ID: 14673758)
1. Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection.
Jacobson JM; Lederman MM; Spritzler J; Valdez H; Tebas P; Skowron G; Wang R; Jackson JB; Fox L; Landay A; Gilbert MJ; O'Neil D; Bancroft L; Al-Harthi L; Jacobson MA; Merigan TC; Glesby MJ;
J Infect Dis; 2003 Dec; 188(12):1804-14. PubMed ID: 14673758
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte colony-stimulating factor increases CD4+ T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: results from a randomized, placebo-controlled trial.
Aladdin H; Ullum H; Dam Nielsen S; Espersen C; Mathiesen L; Katzenstein TL; Gerstoft J; Skinhoj P; Pedersen BK
J Infect Dis; 2000 Mar; 181(3):1148-52. PubMed ID: 10720544
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo-controlled trial of granulocyte-macrophage colony-stimulating factor and nucleoside analogue therapy in AIDS.
Brites C; Gilbert MJ; Pedral-Sampaio D; Bahia F; Pedroso C; Alcantara AP; Sasaki MD; Matos J; Renjifo B; Essex M; Whitmore JB; Agosti JM; Badaro R
J Infect Dis; 2000 Nov; 182(5):1531-5. PubMed ID: 11023477
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of granulocyte-macrophage colony-stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized double-blind, placebo-controlled trial.
Skowron G; Stein D; Drusano G; Melbourne K; Bilello J; Mikolich D; Rana K; Agosti JM; Mongillo A; Whitmore J; Gilbert MJ
J Infect Dis; 1999 Oct; 180(4):1064-71. PubMed ID: 10479132
[TBL] [Abstract][Full Text] [Related]
5. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
[TBL] [Abstract][Full Text] [Related]
6. Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group.
Angel JB; High K; Rhame F; Brand D; Whitmore JB; Agosti JM; Gilbert MJ; Deresinski S
AIDS; 2000 Mar; 14(4):387-95. PubMed ID: 10770541
[TBL] [Abstract][Full Text] [Related]
7. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
O'Brien WA; Hartigan PM; Martin D; Esinhart J; Hill A; Benoit S; Rubin M; Simberkoff MS; Hamilton JD
N Engl J Med; 1996 Feb; 334(7):426-31. PubMed ID: 8552144
[TBL] [Abstract][Full Text] [Related]
8. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
9. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
Goicoechea M; Smith DM; Liu L; May S; Tenorio AR; Ignacio CC; Landay A; Haubrich R
J Infect Dis; 2006 Jul; 194(1):29-37. PubMed ID: 16741879
[TBL] [Abstract][Full Text] [Related]
10. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy.
Flynn PM; Rudy BJ; Douglas SD; Lathey J; Spector SA; Martinez J; Silio M; Belzer M; Friedman L; D'Angelo L; McNamara J; Hodge J; Hughes MD; Lindsey JC;
J Infect Dis; 2004 Jul; 190(2):271-9. PubMed ID: 15216461
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
12. Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy.
Wellons MF; Ottinger JS; Weinhold KJ; Gryszowka V; Sanders LL; Edwards LJ; Gooding ME; Thomasch JR; Bartlett JA
J Infect Dis; 2001 May; 183(10):1522-5. PubMed ID: 11319689
[TBL] [Abstract][Full Text] [Related]
13. Retinal microangiopathy in human immunodeficiency virus infection is related to higher human immunodeficiency virus-1 load in plasma.
Furrer H; Barloggio A; Egger M; Garweg JG;
Ophthalmology; 2003 Feb; 110(2):432-6. PubMed ID: 12578793
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads.
Benveniste O; Flahault A; Rollot F; Elbim C; Estaquier J; Pédron B; Duval X; Dereuddre-Bosquet N; Clayette P; Sterkers G; Simon A; Ameisen JC; Leport C
J Infect Dis; 2005 May; 191(10):1670-9. PubMed ID: 15838794
[TBL] [Abstract][Full Text] [Related]
15. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.
Markowitz M; Saag M; Powderly WG; Hurley AM; Hsu A; Valdes JM; Henry D; Sattler F; La Marca A; Leonard JM
N Engl J Med; 1995 Dec; 333(23):1534-9. PubMed ID: 7477168
[TBL] [Abstract][Full Text] [Related]
16. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
17. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
[TBL] [Abstract][Full Text] [Related]
18. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.
Molina JM; Marcelin AG; Pavie J; Heripret L; De Boever CM; Troccaz M; Leleu G; Calvez V;
J Infect Dis; 2005 Mar; 191(6):840-7. PubMed ID: 15717257
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial.
Gori A; Trabattoni D; Bandera A; Saresella M; Marchetti G; Gazzola L; Biasin M; Rhodes J; McDade H; Panebianco R; Galli M; Moroni M; Ferrante P; Thomas N; Franzetti F; Bray D; Clerici M
Antivir Ther; 2004 Aug; 9(4):603-14. PubMed ID: 15456092
[TBL] [Abstract][Full Text] [Related]
20. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
